These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 19940805

  • 1. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.
    Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [Abstract] [Full Text] [Related]

  • 7. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Abrams P.
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [Abstract] [Full Text] [Related]

  • 8. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group.
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [Abstract] [Full Text] [Related]

  • 9. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.
    Brown GC, Brown MM, Campanella J, Beauchamp GR.
    Am J Ophthalmol; 2005 Oct; 140(4):679-87. PubMed ID: 16226519
    [Abstract] [Full Text] [Related]

  • 10. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.
    Studnička J, Říhová B, Rencová E, Rozsíval P, Dubská Z, Chrapek O, Kolář P, Kandrnal V, Demlová R, Pitrová Š, Řehák J.
    Ophthalmologica; 2013 Oct; 230(1):34-42. PubMed ID: 23751929
    [Abstract] [Full Text] [Related]

  • 11. Ranibizumab vs. pegaptanib: a cost-effectiveness study?
    Wiwanitkit V.
    Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1675; author reply 1677. PubMed ID: 20424851
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [Abstract] [Full Text] [Related]

  • 13. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
    Bansback N, Davis S, Brazier J.
    Eye (Lond); 2007 Dec; 21(12):1455-63. PubMed ID: 17086167
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
    Yanagi Y, Aihara Y, Fukuda T, Hashimoto H.
    Nippon Ganka Gakkai Zasshi; 2011 Sep; 115(9):825-31. PubMed ID: 22073599
    [Abstract] [Full Text] [Related]

  • 18. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
    Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY, FOCUS Study Group.
    Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.